(PS) Adams v. Abbott Laboratories

CourtDistrict Court, E.D. California
DecidedMarch 24, 2025
Docket2:24-cv-00555
StatusUnknown

This text of (PS) Adams v. Abbott Laboratories ((PS) Adams v. Abbott Laboratories) is published on Counsel Stack Legal Research, covering District Court, E.D. California primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
(PS) Adams v. Abbott Laboratories, (E.D. Cal. 2025).

Opinion

1 2 3 4 5 6 7 8 UNITED STATES DISTRICT COURT 9 FOR THE EASTERN DISTRICT OF CALIFORNIA 10 11 ROLAND ADAMS, Case No. 2:24-cv-0555-DC-JDP (PS) 12 Plaintiff, 13 v. FINDINGS AND RECOMMENDATIONS 14 ABBOTT LABORATORIES, 15 Defendant. 16 17 18 Plaintiff Roland Adams brings this action for products liability against Defendant Abbott 19 Laboratories. Defendant moves for a second time to dismiss the complaint on the basis that it 20 fails to state a claim under Federal Rules of Civil Procedure 12(b)(6). For the reasons stated 21 below, I recommend that defendant’s motion be granted and the complaint be dismissed with 22 leave to amend. 23 Procedural History 24 Plaintiff initiated this action in Sacramento Superior Court, and defendant removed it on 25 February 22, 2024. ECF No. 1. Plaintiff alleged claims for strict products liability, negligence, 26 and breach of implied warranty. Id. Following removal, defendant moved to dismiss pursuant to 27 Federal Rules of Civil Procedure 12(b)(6) & (8). ECF No. 4. The court granted defendant’s 28 1 motion and gave plaintiff the opportunity to amend his complaint. ECF Nos. 17 & 21. Plaintiff 2 has done so, ECF No. 18, and defendant moves again to dismiss, ECF No. 26. 3 Allegations 4 Plaintiff’s amended complaint states that he suffers from diabetes and previously used the 5 Libre 2 Sensor, manufactured by defendant, to monitor his diabetic symptoms. ECF No. 18 at 2. 6 In 2022, plaintiff’s doctor changed his prescription to the upgraded Libre 3 sensor in an effort to 7 expanding the monitoring of plaintiff’s diabetic symptoms. Id. Plaintiff first tried to use the new 8 sensor on December 11, 2022.1 Id. In accordance with defendant’s insurer’s recommendation 9 and as advertised in defendant’s promotional materials, plaintiff placed the sensor near the back 10 of his upper arm. Id. at 2-3. Shortly after he placed the sensor, plaintiff noticed blood on his shirt 11 and, once he removed the sensor, he saw that the sensor was completely covered in blood. Id. at 12 3. Plaintiff sought medical treatment after using the sensor; a registered nurse prescribed plaintiff 13 extra strength pain medication and antibiotics. Id. at 4. He was charged $30 for the treatment. 14 Id. 15 Following the incident, plaintiff sent the sensor back to defendant and filed an insurance 16 claim. Id. Before doing so, plaintiff examined the sensor and noticed that it was “atypical, 17 misshapen, and abrasive” and had “an irregular and jagged filament.” Id. at 3-4. Defendant’s 18 insurer denied plaintiff’s claim, stating that the sensor presented no issues after testing and that 19 plaintiff’s injury was likely due to incorrect placement of the device to high on plaintiff’s arm. 20 Id. at 4. 21 Plaintiff alleges three causes of action: strict product liability, negligence, and breach of 22 implied warranty. Id. at 5-8. He seeks $10,000,000 in compensatory damages. Id. at 9. 23 Legal Standards 24 “Dismissal under Rule 12(b)(6) is proper when the complaint either (1) lacks a cognizable 25 legal theory or (2) fails to allege sufficient facts to support a cognizable legal theory.” Somers v. 26

27 1 The amended complaint also makes a passing reference that plaintiff had a similar experience with the sensor when he used it on August 9, 2024. Id. at 4. However, that incident 28 occurred well over two years after plaintiff filed this case and thus will not be considered. 1 Apple, Inc., 729 F.3d 953, 959 (9th Cir. 2013). To survive a motion to dismiss for failure to state 2 a claim, a plaintiff must allege “enough facts to state a claim to relief that is plausible on its face.” 3 Bell Atl. Corp. v. Twombly, 550 U.S. 544, 570 (2007). A claim has facial plausibility when a 4 plaintiff “pleads factual content that allows the court to draw the reasonable inference that the 5 defendant is liable for the misconduct alleged.” Ashcroft v. Iqbal, 556 U.S. 662, 678 (2009). 6 In deciding motions under Rule 12(b)(6), the court generally considers only allegations 7 contained in the pleadings, exhibits attached to the complaint, and matters properly subject to 8 judicial notice, and construes all well-pleaded material factual allegations in the light most 9 favorable to the nonmoving party. Chubb Custom Ins. Co. v. Space Sys./Loral, Inc., 710 F.3d 10 946, 956 (9th Cir. 2013); Akhtar v. Mesa, 698 F.3d 1202, 1212 (9th Cir. 2012). In certain 11 circumstances, the court may also consider documents referenced in but not included with the 12 complaint, or that form a basis of plaintiff’s claims. See United States v. Ritchie, 342 F.3d 903, 13 907 (9th Cir. 2003). 14 Discussion 15 The first amended complaint alleges three causes of action: strict products liability, 16 negligence, and breach of warranty. ECF No. 1. For the foregoing reasons, I find that the 17 amended complaint has failed to state a claim and recommend that this action be dismissed with 18 leave to amend. 19 Strict Products Liability: Design Defect 20 Plaintiff has advanced a theory of design defect. See ECF No. 18 at 5. Defendant asserts 21 three independent arguments for why plaintiff’s strict product liability claim fails. Defendant 22 argues: first that California does not recognize a design defect claim for prescription medical 23 devices. ECF No. 26 at 5. Second, that plaintiff has not alleged that there was an actual defect in 24 the design of the product. Id. at 6. And finally, that plaintiff has not plausibly alleged a design 25 defect under either the Risk Benefit Test or the Consumer Expectations Test. Id. at 7. In 26 response, plaintiff asserts that his pro se status should shield him from being held to the same 27 standard as an attorney and that this case cannot be properly adjudicated with discovery. ECF 28 No. 28. 1 A design defect claim requires that a product be built in accordance with its intended 2 specifications, and that the design itself is inherently defective. Barker v. Lull Eng’g Co., 20 3 Cal.3d 413, 429 (1978). To be actionable under the design defect theory of product liability, a 4 product design must be defective under either the Consumer Expectations Test or the Risk- 5 Benefit Test. Soule v. Gen. Motors Corp., 8 Cal. 4th 548, 566-67 (1994). The Consumer 6 Expectations Test considers whether the product “fail[s] to perform as safely as its ordinary 7 consumers would expect when used in an intended or reasonably foreseeable manner.” Lucas v. 8 City of Visalia, 726 F. Supp. 2d 1149, 1154 (E.D. Cal. 2010). Alternatively, the Risk-Benefit 9 Test considers whether “the design embodies ‘excessive preventable danger,’ that is, the risk of 10 danger inherent in the design outweighs the benefits of such design.” Id. Of particular relevance 11 here, California law precludes strict liability predicated on a theory of design defect against 12 manufacturers of prescription medical devices. See Garrett v. Howmedica Osteonics Corp., 214 13 Cal. App. 4th 173, 182 (2013) (recognizing “an exemption from design defect strict products 14 liability for all implanted medical devices that are available only through the services of a 15 physician”). 16 Plaintiff alleges that the sensor was prescribed by his physician and that it is a medical 17 device. ECF No. 18 at 2.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Bell Atlantic Corp. v. Twombly
550 U.S. 544 (Supreme Court, 2007)
Ashcroft v. Iqbal
556 U.S. 662 (Supreme Court, 2009)
Javiad Akhtar v. J. Mesa
698 F.3d 1202 (Ninth Circuit, 2012)
United States v. Mills
710 F.3d 5 (First Circuit, 2013)
Stacie Somers v. Apple, Inc.
729 F.3d 953 (Ninth Circuit, 2013)
Clemens v. DaimlerChrysler Corp.
534 F.3d 1017 (Ninth Circuit, 2008)
Burr v. Sherwin Williams Co.
268 P.2d 1041 (California Supreme Court, 1954)
Soule v. General Motors Corp.
882 P.2d 298 (California Supreme Court, 1994)
In Re Johnson
475 P.2d 841 (California Supreme Court, 1970)
Keith v. Buchanan
173 Cal. App. 3d 13 (California Court of Appeal, 1985)
Osborne v. Subaru of America, Inc.
198 Cal. App. 3d 646 (California Court of Appeal, 1988)
Gonzalez v. Autoliv ASP, Inc.
64 Cal. Rptr. 3d 908 (California Court of Appeal, 2007)
In Re Coordinated Latex Glove Litigation
121 Cal. Rptr. 2d 301 (California Court of Appeal, 2002)
American Suzuki Motor Corp. v. Superior Court
37 Cal. App. 4th 1291 (California Court of Appeal, 1995)
Lucas v. City of Visalia
726 F. Supp. 2d 1149 (E.D. California, 2010)
Merrill v. Navegar, Inc.
28 P.3d 116 (California Supreme Court, 2001)

Cite This Page — Counsel Stack

Bluebook (online)
(PS) Adams v. Abbott Laboratories, Counsel Stack Legal Research, https://law.counselstack.com/opinion/ps-adams-v-abbott-laboratories-caed-2025.